Group One Trading’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.18M | Buy |
151,700
+102,100
| +206% | +$2.3M | 0.01% | 1662 |
|
|
2025
Q4 | $1.14M | Buy |
49,600
+39,200
| +377% | +$1.29M | ﹤0.01% | 2771 |
|
|
2025
Q3 | $313K | Sell |
10,400
-18,800
| -64% | -$564K | ﹤0.01% | 4177 |
|
|
2025
Q2 | $1.06M | Sell |
29,200
-2,500
| -8% | -$90.1K | ﹤0.01% | 2712 |
|
|
2025
Q1 | $1.15M | Buy |
31,700
+23,200
| +273% | +$965K | ﹤0.01% | 2332 |
|
|
2024
Q4 | $358K | Sell |
8,500
-6,500
| -43% | -$322K | ﹤0.01% | 3447 |
|
|
2024
Q3 | $833K | Hold |
15,000
| – | – | ﹤0.01% | 2453 |
|
|
2024
Q2 | $617K | Hold |
15,000
| – | – | ﹤0.01% | 2373 |
|
|
2024
Q1 | $700K | Hold |
15,000
| – | – | ﹤0.01% | 2419 |
|
|
2023
Q4 | $717K | Buy |
15,000
+7,000
| +88% | +$271K | ﹤0.01% | 2768 |
|
|
2023
Q3 | $285K | Buy |
8,000
+4,800
| +150% | +$190K | ﹤0.01% | 3478 |
|
|
2023
Q2 | $148K | Sell |
3,200
-13,000
| -80% | -$603K | ﹤0.01% | 4248 |
|
|
2023
Q1 | $650K | Sell |
16,200
-500
| -3% | -$21.5K | ﹤0.01% | 2512 |
|
|
2022
Q4 | $774K | Buy |
16,700
+16,500
| +8,250% | +$649K | ﹤0.01% | 2644 |
|
|
2022
Q3 | $8K | Buy |
+200
| New | +$10.3K | ﹤0.01% | 6642 |
|
|
2020
Q3 | – | Sell |
-400
| Closed | -$31K | – | 6475 |
|
|
2020
Q2 | $31K | Sell |
400
-6,800
| -94% | -$450K | ﹤0.01% | 4627 |
|
|
2020
Q1 | $320K | Buy |
7,200
+2,200
| +44% | +$114K | ﹤0.01% | 2381 |
|
|
2019
Q4 | $214K | Buy |
+5,000
| New | +$206K | ﹤0.01% | 3122 |
|
|
2018
Q4 | – | Sell |
-3,000
| Closed | -$229K | – | 5314 |
|
|
2018
Q3 | $229K | Buy |
+3,000
| New | +$244K | ﹤0.01% | 2923 |
|
|
2018
Q1 | – | Sell |
-4,000
| Closed | -$186K | – | 5228 |
|
|
2017
Q4 | $186K | Hold |
4,000
| – | – | ﹤0.01% | 2966 |
|
|
2017
Q3 | $213K | Buy |
+4,000
| New | +$237K | ﹤0.01% | 2716 |
|
|
2017
Q2 | – | Sell |
-2,000
| Closed | -$136K | – | 5017 |
|
|
2017
Q1 | $136K | Sell |
2,000
-11,400
| -85% | -$869K | ﹤0.01% | 2786 |
|
|
2016
Q4 | $942K | Buy |
13,400
+13,300
| +13,300% | +$944K | 0.01% | 1350 |
|
|
2016
Q3 | $7K | Sell |
100
-5,000
| -98% | -$319K | ﹤0.01% | 4147 |
|
|
2016
Q2 | $249K | Sell |
5,100
-6,800
| -57% | -$440K | ﹤0.01% | 2254 |
|
|
2016
Q1 | $753K | Buy |
11,900
+9,300
| +358% | +$609K | 0.01% | 1389 |
|
|
2015
Q4 | $292K | Sell |
2,600
-4,700
| -64% | -$470K | ﹤0.01% | 2222 |
|
|
2015
Q3 | $703K | Sell |
7,300
-5,500
| -43% | -$630K | 0.01% | 1521 |
|
|
2015
Q2 | $1.31M | Buy |
12,800
+5,200
| +68% | +$404K | 0.02% | 1023 |
|
|
2015
Q1 | $472K | Buy |
7,600
+7,500
| +7,500% | +$417K | 0.01% | 1649 |
|
|
2014
Q4 | $4K | Sell |
100
-2,700
| -96% | -$124K | ﹤0.01% | 4548 |
|
|
2014
Q3 | $158K | Buy |
2,800
+1,800
| +180% | +$90.6K | ﹤0.01% | 2575 |
|
|
2014
Q2 | $45K | Buy |
+1,000
| New | +$41.2K | ﹤0.01% | 3627 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Group One Trading's RARE Position: Q1 2026 in Review
Group One Trading increased its Ultragenyx Pharmaceutical (RARE) stake by 504% in Q1 2026, buying an estimated $2.63M and bringing the position to 140,166 shares worth $2.94M. The position accounts for 0.01% of the portfolio, ranked #1721.
Group One Trading first reported a position in RARE in Q2 2014 and has held it in 28 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Group One Trading held 140,166 shares of Ultragenyx Pharmaceutical worth $2.94M as of Q1 2026.
- Group One Trading bought 116,958 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.63M.
- Ultragenyx Pharmaceutical made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1721 holding.
- Group One Trading first reported a position in Ultragenyx Pharmaceutical in Q2 2014 and has held it in 28 quarters since.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.